CA2394588A1 - Controlled release kcl tablet formulations - Google Patents
Controlled release kcl tablet formulations Download PDFInfo
- Publication number
- CA2394588A1 CA2394588A1 CA002394588A CA2394588A CA2394588A1 CA 2394588 A1 CA2394588 A1 CA 2394588A1 CA 002394588 A CA002394588 A CA 002394588A CA 2394588 A CA2394588 A CA 2394588A CA 2394588 A1 CA2394588 A1 CA 2394588A1
- Authority
- CA
- Canada
- Prior art keywords
- weight
- ethylcellulose
- potassium chloride
- tablet
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
In accordance with the present invention, controlled release potassium chloride tablets are prepared from a pharmaceutical composition comprised of potassium chloride particles coated with a membrane of plasticized water swellable/soluble polymer. The coated Potassium chloride particles are blend ed with pharmaceutical excipients and compressed into tablets.
Description
Controlled Release KCI Tablet Formulations Background of the Invention There is a high incidence of severe potassium deficiency in patients treated simultaneously with diuretics and carbenoxolone. In order to maintain the extracellular and intracellular concentrations of potassium within relatively narrow limits, large doses of potassium are required. These doses are released in the body in a controlled release fashion in order to avoid achieving life-threatening toxicity. The strengths of the most dosage forms available in the market place are 8 and 10 mEq KCl capsules or tablets. Since a 20 mEq KCl capsule formulation (exceeding 2 g in weight) is not feasible, there is a need for a 20 mEq KCl tablet formulation. There is a 20 mEq KCl tablet that is commercially available under the tradename, K-DUR 20, based on KCl granules coated with a coating composition comprising of ethyl cellulose (Ethocel Standard Premium 100 or Ethocel Medium 100 from Dow Chemical) and hydroxypropyl cellulose (Klucel from Hercules) using a fluid bed granulator which is made under U.S. Patent 4,863,743 issued to C. Hsiao and T.
Chou of Key Pharmaceuticals, Inc.
Summary of the Invention An object of the present invention is to provide a method for manufacturing pharmaceutically elegant KCl tablets having sustained release properties (e.g., releasing not more than 40% in one hr and not less than 80% over 8 hrs when tested in USP
Apparatus 2 (Paddles @ 50 rpm) in purified water. Another object is to provide tablets with controlled release characteristics, thereby providing treatments for potassium deficiency in humans while minimizing adverse side effects if possible. Since 20 mEq active is equivalent to almost 1500 mg Kcl, it is difficult to provide this dosage in a single tablet, which can deliver an effective daily dose of potassium without being unduly large for swallowing. A more particular but non-limiting further objective of the invention is to provide tablets of total tablet weight of about 2 g (preferably under 2 g) with acceptable hardness (not less than 10 kP) and friability (not more than 1.5%).
US Patent 5,422,122 teaches the art of making a pharmaceutical dosage forn~
by first forming KCl microcapsules by coacervation in a cyclohexane solution of ethylcellulose, overcoating the microcapsules with hydroxypropylcellulose and compressing the resulting microcapsules into 20 mEq KCl tablets. This patent is incorporated here in its entirety. Microencapsulated KCl granules produced by solvent coacervation of ethylcellulose are often Glassy hard granules with poor compactibility characteristics. In order to improve the compressibility/compactibility of the microcapsules, film coating with a variety of plasticized, pharnlaceutically acceptable polymeric materials was attempted.
Polymeric materials found suitable for improving ethylcellulose coated KCl microcapsules include acacia, alginic acid or its salt, com starch, gelatin, xanthan gum, polyvinylpyrrolidone (PVP), sodium carboxymethylcellulose, methylcellulose, low molecular weight ethylcellulose (EC) and hydroxypropylmethyl cellulose (HPMC) alone or in combination. Different plasticizers such as triacetin, triethyl citrate, dibutyl sebacate, polyethylene glycol of molecular weight ranging from 200 to 8,000, were evaluated alone or in combination. These attempts have resulted in pharnlaceutically elegant 20mEq KCl capsule-shaped tablets weighing about 2 g (generally less) and having controlled release properties (releasing not more than 40% in one hr and not less than 80% over 8 hrs) when tested in USP Apparatus 2 (Paddles @
50 rpm) in purified water.
Thus, one manifestation of the present invention is an improved 20 mEq KCl controlled release dosage form prepared from a multiplicity of ethylcellulose microencapsulated potassium chloride crystals, which are further coated with a plasticized water swellable/soluble polymer or a blend. These membrane coated granules are capable of being compressed into pharmaceutically elegant, easily swallowable 20 mEq KCl tablets of acceptable hardness and friability. Of course other KCl dosages are also within the scope of the invention. Another manifestation of the present invention is a method for preparing microencapsulated KCI crystals and a method for preparing a KCL tablet.
Detailed Description of the Invention A plurality of potassium chloride crystals, preferably from about 20 mesh to about 70 mesh, more preferably from about 30 mesh to about 50 mesh, are coated with two distinct layers. rl'he first layer applied to the crystals is composed of ethylcellulose.
Utilization of a high viscosity ethylcellulose such as one with a viscosity of from about 90 to about 110 cp, e.g., Ethocel 100 (Dow Chemical Corp.) allows the crystals to retain their diffusion controlling characteristics even after compression into a tablet form. The ethylcellulose may be applied by any suitable technique known in the art, but is preferably applied by coacervation using polyethylene as a phase separator as described in U. S. Patent 5,422,122. If coacervation is used, trace amounts of the phase separator may be present in the first layer, preferably in an amount less than about one percent by weight of the ethylcellulose coated crystals.
The ethylcellulose layer is preferably applied to the KCl crystals in an amount of about 8 to about 20 percent, more preferably from about 11 to about 15 percent, of the total weight of the uncoated potassium chloride crystals. This first layer controls the release of the potassium chloride over time, total release time being proportionally dependent upon the thickness of ethylcellulose. After application of the ethylcellulose, a drying step should preferably be carried out for such a time period and at such temperatures so that the microencapsulated crystals do not adhere to one another. The resultant ethylcellulose encapsulated potassium chloride microcapsules are preferably of such a size that less than 5% are greater than 20 mesh.
A second, discrete layer of at least one hydrophilic (water swellable/soluble) polymer coating, is applied over the first layer of ethylcellulose.
Hydrophilic polymer coatings include, but are not necessarily limited to acacia, alginic acid or its salt, corn starch, gelatin, xanthan gum, polyvinylpyrrolidone (PVP), sodium carboxymethylcellulose, methylcellulose, low molecular weight ethylcellulose (Ethocel with a viscosity from about 4 to 20 cps) and hydroxypropylmethyl cellulose (HPMC) such as Methocel ES or l~.
These hydrophilic polymers can be used alone or in combination.
In accordance with the invention the hydrophilic polymer layer is plasticized.
Suitable plasticizers include triacetin, triethyl citrate, dibutyl sebacate (DBS), polyethylene glycol (PEG) of molecular weight ranging from 200 to 8,000 (e.g., a blend of PEG 400 and PEG 4000). The plasticizers can be used alone or in combination. The plasticizer is typically used in an amount of about 2 to 30% based on the combined weight of the hydrophillic polymer and plasticizer. The amount will vary with the type of plasticizer and the nature of the hydrophillic polymer. For example for HPMC and PEG400 the ratio can vary ti-om about 7U/3U to 9U/lU. With PVP, DBS or triethyl citrate can be used as the plasticizer in a ratio of 94/6 to 97/3.
The plasticized hydrophilic layer is applied by conventional techniques, such as from an aqueous solution using a fluidized bed coater, to the preformed layer of ethylcellulose. The hydrophilic polymer coating layer inclusive of the plasticizer is applied in an amount of about 0.5 to 5% w/w (preferably about 1 to 3% w/w and still more typically 2% w/w) of the weight of the ethylcellulose coated crystals.
The hydrophilic polymer does not significantly diffuse into the ethylcellulose, but rather forms a distinct second layer. The first membrane of ethylcellulose coacervated in the absence of any plasticizer can be easily distinguishable from the plasticized polymeric membrane by microscopic/spectroscopic techniques. As this layer is soluble to gastric fluids, the hydrophilic polymer coating dissolves following ingestion of the resultant tablet. For all practical purposes, it does not contribute to the controlled release of potassium chloride.
Rather, the hydrophilic polymer coating is present primarily as a binder material so that a high dosage rate tablet can be formed with a minimal amount of conventional excipients and low compaction pressures to allow minimal disruption of the rate controlling ethylcellulose membrane. In addition, this formulation allows the microencapsulated potassium chloride to be dispersed essentially intact over a wide area, reducing the risk of gastric irritation.
After the hydrophilic polymer coating layer is applied, the now twice coated crystals are subjected to a final drying step. The resultant coated potassium chloride microcapsules are preferably of such a size that less than 15%, are greater than 20 mesh. The coated crystals may then be formed into tablets by compression using conventional techniques. Preferably a minimal amount of excipients, no more than about 15%
more preferably no more than 12%, and most preferably no more than 7% by weight based on the weight of the final dosage tablet, is added to the coated crystals prior to compression. The terns "excipients," as used herein, refers to any additional pharmaceutically acceptable ingredients which may be used in a tablet. These excipients include, but are not limited to, ingredients such as diluents or binders, disintegrants, wetting agents, and lubricating agents.
Representative binders include, but are not limited to, Klucel Registered LF
(hydroxypropylcellulose) and Avicel Registered (microcrystalline cellulose).
Disintegrants include, but are not limited to, cornstarch, lactose, mannitol, sucrose, Avicel Registered (microcrystalline cellulose), Primogel Registered (sodium carboxymethyl starch, WO 01/43725 PCT/iJS00/33924 ~;mcompress Registered (dibasic catcmm phosphate dihydrate), Crospovidone Registered (cross linked polyvinyl pyrrolidone), and tricalcium phosphate. Wetting agents include, but are not limited to sodium lauryl sulfate. Lubricating agents include, but are not limited to stearates (e.g. magnesium, calcium, and sodium), stearic acid, Sterotex Registered, talc, waxes, and Stearowet Registered.
In a particular embodiment of the invention, the ethylcellulose KCl microcapsules coated with a plasticized polymer coating solution are blended with a diluent, preferably microcrystalline cellulose, optionally a disintegrant and/or a lubricant, and compressed into capsule shaped tablets. In one embodiment, a disintegrant such as crosslinked PVP (Crospovidone) or sodium starch glycolate at a level of 0.2 to 2% w/w and/or a lubricant/surfactant such as sodium lauryl sulfate is optionally blended with the compression mix. In the course of these investigations, it was discovered that sodium lauryl sulfate, widely used as a surfactant produce strong tablets with low friability. It was also discovered that microcapsules fluid bed coated with the plasticized polymeric systems discussed in this patent application could be compressed into strong tablets with low friability without a lubricant (magnesium stearate) or a surfactant (sodium lauryl sulfate).
The final tablets will contain a pharmaceutically acceptable amount of potassium chloride. Acceptable daily dosages may be found in The Physicians' Desk Reference, 45th ed. ( 1991 ), e.g., 20-200 mEq/day thereof, preferably from about 8 mEq to about 20 mEq. The pharmaceutically elegant 20 mEq Microcaps KC1 tablets will exhibit sustained release properties (releasing not more than 40% in one hr and not less than 80%
over 8 hrs when tested in USP Apparatus 2 (Paddles @ 50 rpm) in purified water, thereby providing treatments for potassium deficiency in humans with minimal adverse side effects.
Typical formulations are given in Example 1-3. Unless otherwise indicated all parts are by weight.
Ingredients Example 1 Example 2 Example 3 Film Coating Microcaps KCI 1714.3 1714.3 1714.3 HPMC ES 6.2 30.8 31.5 PEG 400 2.6 13.2 1 / 1 PEG 400/PEG 4000 3.5 Compression Mix Film coated 1723.1 1758.3 1749.3 KCl Microcryst. 186.2 200.9 174.9 Cellulose Crosslinked 39.2 19.9 PVP
Sod. Lauryl 9.8 9.9 sulfate Total Tablet 1960.2 1989.0 1943.2 weight Example 1 Microcaps KCl granules (KC1 crystals microencapsulated in ethylcellulose) with a 87.5 KC1 content were coated with an aqueous solution of hydroxypropylmethyl cellulose (HPMC) and polyethylene glycol 400 (PEG 400) at a ratio of 77/23 to achieve a weight gain of 0.5% w/w. The film coated granules were blended with microcrystalline cellulose (MCC), crosslinked PVP and sodium lauryl sulfate in an amounts of at 9.5%, 2.0%
and 0.5% w/w, respectively and compressed into tablets weighing 1960 mg on a rotary tablet press. These tablets containing 1500 mg of Microcaps KCl release slowly over a period of hrs when dissolved in O.1N HCl using USP Apparatus 2.
Example 2 Microcaps KCl granules (KCl crystals microencapsulated in ethylcellulose) with a 87.5 KCl content were coated to achieve a weight gain of 2.5% w/w with an aqueous solution of HPMC and PEG 400 at a ratio of 77/23. The film coated granules were blended with microcrystalline cellulose and crosslinked PVP at 10.0 and 1.0% w/w, respectively and compressed into tablets weighing 1989 mg on a rotary tablet press. These tablets containing 1500 mg active as Microcaps KCl release slowly over a period of 10 hrs when dissoluted in 0.1 N HCL using USP Apparatus 2.
IlJxample 3 Microcaps KCl granules (KCl crystals microencapsulated in ethylcellulose) with a 87.5 KCl content were coated with an aqueous solution of HPMC and PEG
400 at a ratio of 77/23 to achieve a weight gain of 1.0% w/w. The film coated granules were blended with microcrystalline cellulose, crosslinked PVP and magnesium stearate at 9.5%, 2.0 and 0.5% w/w, respectively and compressed into tablets weighing 1968 mg on a rotary tablet press. These pharmaceutically elegant tablets containing 1500 mg active as Microcaps KCl release slowly over a period of 10 hrs when dissoluted in O.1N HC1 using USP
Apparatus 2.
Ingredients Example 4 Example 5 Example 6 Film Coating Microcaps KCl 1714.3 1714.3 1714.3 PVP (K-30) 31.5 31.5 1 / 1 Ethocel/PVP 31.5 1/1 PEG 400/PEG 4000 3.5 Tri-ethyl citrate 3.5 Dibutyl sebacate 3.5 Compression Mix Film coated KCl 1749.3 1749.3 1749.3 Microcryst. Cellulose194.4 196.6 194.3 Crosslinked PVP 19.6 Total Tablet weight1943.7 1965.5 1943.7 _7_ Example 4 Microcaps KCl granules (KC1 crystals microencapsulated in ethylcellulose) with a 87.5 KCI
content were coated with an aqueous solution of polyvinylpyrrolidone (PVP K-30) containing 1:1 PEG 400/PEG 4000 at 10% w/w to achieve a weight gain of 2.0%
w/w. The film coated granules were blended with microcrystalline cellulose at 10.0% w/w and compressed into tablets weighing 1944 mg on a rotary tablet press. These tablets containing 1500 mg active as Microcaps KCl release slowly over a period of 10 hrs when dissoluted in O.1N HCl using USP Apparatus 2.
Example Microcaps KCl granules (KCl crystals microencapsulated in ethylcellulose) with a 87.5 KCl content were coated to achieve a weight gain of 2.0% w/w with an aqueous solution of PVP
and tri-ethyl citrate at a ratio of 97/03. The film coated granules were blended with microcrystalline cellulose and crosslinked PVP at 10.0 and 1.0% w/w, respectively and compressed into tablets weighing 1965 mg on a rotary tablet press. These tablets containing 1500 mg active as Microcaps KCl release slowly over a period of 10 hrs when dissoluted in O.1N HCl using USP Apparatus 2.
Example 6 Microcaps KCl granules (KCl crystals microencapsulated in ethylcellulose) with a 87.5 KC1 content were coated with an IPA/acetone solution of PVP/Ethocel/DBS at a ratio of 48/48/04 to achieve a weight gain of about 2.0% w/w. The film coated granules were blended with microcrystalline cellulose at 10% w/w and compressed into tablets weighing 1944 mg on a rotary tablet press. These pharmaceutically elegant tablets containing 1500 mg active as Microcaps KC1 release slowly over a period of 10 hrs when dissoluted in O.1N
HCl using USP Apparatus 2.
_g_ The above examples are provided to show how to practice the present invention and are not intended to be exhaustive or to include all obvious modifications and variations which will become apparent to those skilled in formulation development.
However, all these modifications are within the scope of the present invention and by the following claims:
What is claimed is:
Chou of Key Pharmaceuticals, Inc.
Summary of the Invention An object of the present invention is to provide a method for manufacturing pharmaceutically elegant KCl tablets having sustained release properties (e.g., releasing not more than 40% in one hr and not less than 80% over 8 hrs when tested in USP
Apparatus 2 (Paddles @ 50 rpm) in purified water. Another object is to provide tablets with controlled release characteristics, thereby providing treatments for potassium deficiency in humans while minimizing adverse side effects if possible. Since 20 mEq active is equivalent to almost 1500 mg Kcl, it is difficult to provide this dosage in a single tablet, which can deliver an effective daily dose of potassium without being unduly large for swallowing. A more particular but non-limiting further objective of the invention is to provide tablets of total tablet weight of about 2 g (preferably under 2 g) with acceptable hardness (not less than 10 kP) and friability (not more than 1.5%).
US Patent 5,422,122 teaches the art of making a pharmaceutical dosage forn~
by first forming KCl microcapsules by coacervation in a cyclohexane solution of ethylcellulose, overcoating the microcapsules with hydroxypropylcellulose and compressing the resulting microcapsules into 20 mEq KCl tablets. This patent is incorporated here in its entirety. Microencapsulated KCl granules produced by solvent coacervation of ethylcellulose are often Glassy hard granules with poor compactibility characteristics. In order to improve the compressibility/compactibility of the microcapsules, film coating with a variety of plasticized, pharnlaceutically acceptable polymeric materials was attempted.
Polymeric materials found suitable for improving ethylcellulose coated KCl microcapsules include acacia, alginic acid or its salt, com starch, gelatin, xanthan gum, polyvinylpyrrolidone (PVP), sodium carboxymethylcellulose, methylcellulose, low molecular weight ethylcellulose (EC) and hydroxypropylmethyl cellulose (HPMC) alone or in combination. Different plasticizers such as triacetin, triethyl citrate, dibutyl sebacate, polyethylene glycol of molecular weight ranging from 200 to 8,000, were evaluated alone or in combination. These attempts have resulted in pharnlaceutically elegant 20mEq KCl capsule-shaped tablets weighing about 2 g (generally less) and having controlled release properties (releasing not more than 40% in one hr and not less than 80% over 8 hrs) when tested in USP Apparatus 2 (Paddles @
50 rpm) in purified water.
Thus, one manifestation of the present invention is an improved 20 mEq KCl controlled release dosage form prepared from a multiplicity of ethylcellulose microencapsulated potassium chloride crystals, which are further coated with a plasticized water swellable/soluble polymer or a blend. These membrane coated granules are capable of being compressed into pharmaceutically elegant, easily swallowable 20 mEq KCl tablets of acceptable hardness and friability. Of course other KCl dosages are also within the scope of the invention. Another manifestation of the present invention is a method for preparing microencapsulated KCI crystals and a method for preparing a KCL tablet.
Detailed Description of the Invention A plurality of potassium chloride crystals, preferably from about 20 mesh to about 70 mesh, more preferably from about 30 mesh to about 50 mesh, are coated with two distinct layers. rl'he first layer applied to the crystals is composed of ethylcellulose.
Utilization of a high viscosity ethylcellulose such as one with a viscosity of from about 90 to about 110 cp, e.g., Ethocel 100 (Dow Chemical Corp.) allows the crystals to retain their diffusion controlling characteristics even after compression into a tablet form. The ethylcellulose may be applied by any suitable technique known in the art, but is preferably applied by coacervation using polyethylene as a phase separator as described in U. S. Patent 5,422,122. If coacervation is used, trace amounts of the phase separator may be present in the first layer, preferably in an amount less than about one percent by weight of the ethylcellulose coated crystals.
The ethylcellulose layer is preferably applied to the KCl crystals in an amount of about 8 to about 20 percent, more preferably from about 11 to about 15 percent, of the total weight of the uncoated potassium chloride crystals. This first layer controls the release of the potassium chloride over time, total release time being proportionally dependent upon the thickness of ethylcellulose. After application of the ethylcellulose, a drying step should preferably be carried out for such a time period and at such temperatures so that the microencapsulated crystals do not adhere to one another. The resultant ethylcellulose encapsulated potassium chloride microcapsules are preferably of such a size that less than 5% are greater than 20 mesh.
A second, discrete layer of at least one hydrophilic (water swellable/soluble) polymer coating, is applied over the first layer of ethylcellulose.
Hydrophilic polymer coatings include, but are not necessarily limited to acacia, alginic acid or its salt, corn starch, gelatin, xanthan gum, polyvinylpyrrolidone (PVP), sodium carboxymethylcellulose, methylcellulose, low molecular weight ethylcellulose (Ethocel with a viscosity from about 4 to 20 cps) and hydroxypropylmethyl cellulose (HPMC) such as Methocel ES or l~.
These hydrophilic polymers can be used alone or in combination.
In accordance with the invention the hydrophilic polymer layer is plasticized.
Suitable plasticizers include triacetin, triethyl citrate, dibutyl sebacate (DBS), polyethylene glycol (PEG) of molecular weight ranging from 200 to 8,000 (e.g., a blend of PEG 400 and PEG 4000). The plasticizers can be used alone or in combination. The plasticizer is typically used in an amount of about 2 to 30% based on the combined weight of the hydrophillic polymer and plasticizer. The amount will vary with the type of plasticizer and the nature of the hydrophillic polymer. For example for HPMC and PEG400 the ratio can vary ti-om about 7U/3U to 9U/lU. With PVP, DBS or triethyl citrate can be used as the plasticizer in a ratio of 94/6 to 97/3.
The plasticized hydrophilic layer is applied by conventional techniques, such as from an aqueous solution using a fluidized bed coater, to the preformed layer of ethylcellulose. The hydrophilic polymer coating layer inclusive of the plasticizer is applied in an amount of about 0.5 to 5% w/w (preferably about 1 to 3% w/w and still more typically 2% w/w) of the weight of the ethylcellulose coated crystals.
The hydrophilic polymer does not significantly diffuse into the ethylcellulose, but rather forms a distinct second layer. The first membrane of ethylcellulose coacervated in the absence of any plasticizer can be easily distinguishable from the plasticized polymeric membrane by microscopic/spectroscopic techniques. As this layer is soluble to gastric fluids, the hydrophilic polymer coating dissolves following ingestion of the resultant tablet. For all practical purposes, it does not contribute to the controlled release of potassium chloride.
Rather, the hydrophilic polymer coating is present primarily as a binder material so that a high dosage rate tablet can be formed with a minimal amount of conventional excipients and low compaction pressures to allow minimal disruption of the rate controlling ethylcellulose membrane. In addition, this formulation allows the microencapsulated potassium chloride to be dispersed essentially intact over a wide area, reducing the risk of gastric irritation.
After the hydrophilic polymer coating layer is applied, the now twice coated crystals are subjected to a final drying step. The resultant coated potassium chloride microcapsules are preferably of such a size that less than 15%, are greater than 20 mesh. The coated crystals may then be formed into tablets by compression using conventional techniques. Preferably a minimal amount of excipients, no more than about 15%
more preferably no more than 12%, and most preferably no more than 7% by weight based on the weight of the final dosage tablet, is added to the coated crystals prior to compression. The terns "excipients," as used herein, refers to any additional pharmaceutically acceptable ingredients which may be used in a tablet. These excipients include, but are not limited to, ingredients such as diluents or binders, disintegrants, wetting agents, and lubricating agents.
Representative binders include, but are not limited to, Klucel Registered LF
(hydroxypropylcellulose) and Avicel Registered (microcrystalline cellulose).
Disintegrants include, but are not limited to, cornstarch, lactose, mannitol, sucrose, Avicel Registered (microcrystalline cellulose), Primogel Registered (sodium carboxymethyl starch, WO 01/43725 PCT/iJS00/33924 ~;mcompress Registered (dibasic catcmm phosphate dihydrate), Crospovidone Registered (cross linked polyvinyl pyrrolidone), and tricalcium phosphate. Wetting agents include, but are not limited to sodium lauryl sulfate. Lubricating agents include, but are not limited to stearates (e.g. magnesium, calcium, and sodium), stearic acid, Sterotex Registered, talc, waxes, and Stearowet Registered.
In a particular embodiment of the invention, the ethylcellulose KCl microcapsules coated with a plasticized polymer coating solution are blended with a diluent, preferably microcrystalline cellulose, optionally a disintegrant and/or a lubricant, and compressed into capsule shaped tablets. In one embodiment, a disintegrant such as crosslinked PVP (Crospovidone) or sodium starch glycolate at a level of 0.2 to 2% w/w and/or a lubricant/surfactant such as sodium lauryl sulfate is optionally blended with the compression mix. In the course of these investigations, it was discovered that sodium lauryl sulfate, widely used as a surfactant produce strong tablets with low friability. It was also discovered that microcapsules fluid bed coated with the plasticized polymeric systems discussed in this patent application could be compressed into strong tablets with low friability without a lubricant (magnesium stearate) or a surfactant (sodium lauryl sulfate).
The final tablets will contain a pharmaceutically acceptable amount of potassium chloride. Acceptable daily dosages may be found in The Physicians' Desk Reference, 45th ed. ( 1991 ), e.g., 20-200 mEq/day thereof, preferably from about 8 mEq to about 20 mEq. The pharmaceutically elegant 20 mEq Microcaps KC1 tablets will exhibit sustained release properties (releasing not more than 40% in one hr and not less than 80%
over 8 hrs when tested in USP Apparatus 2 (Paddles @ 50 rpm) in purified water, thereby providing treatments for potassium deficiency in humans with minimal adverse side effects.
Typical formulations are given in Example 1-3. Unless otherwise indicated all parts are by weight.
Ingredients Example 1 Example 2 Example 3 Film Coating Microcaps KCI 1714.3 1714.3 1714.3 HPMC ES 6.2 30.8 31.5 PEG 400 2.6 13.2 1 / 1 PEG 400/PEG 4000 3.5 Compression Mix Film coated 1723.1 1758.3 1749.3 KCl Microcryst. 186.2 200.9 174.9 Cellulose Crosslinked 39.2 19.9 PVP
Sod. Lauryl 9.8 9.9 sulfate Total Tablet 1960.2 1989.0 1943.2 weight Example 1 Microcaps KCl granules (KC1 crystals microencapsulated in ethylcellulose) with a 87.5 KC1 content were coated with an aqueous solution of hydroxypropylmethyl cellulose (HPMC) and polyethylene glycol 400 (PEG 400) at a ratio of 77/23 to achieve a weight gain of 0.5% w/w. The film coated granules were blended with microcrystalline cellulose (MCC), crosslinked PVP and sodium lauryl sulfate in an amounts of at 9.5%, 2.0%
and 0.5% w/w, respectively and compressed into tablets weighing 1960 mg on a rotary tablet press. These tablets containing 1500 mg of Microcaps KCl release slowly over a period of hrs when dissolved in O.1N HCl using USP Apparatus 2.
Example 2 Microcaps KCl granules (KCl crystals microencapsulated in ethylcellulose) with a 87.5 KCl content were coated to achieve a weight gain of 2.5% w/w with an aqueous solution of HPMC and PEG 400 at a ratio of 77/23. The film coated granules were blended with microcrystalline cellulose and crosslinked PVP at 10.0 and 1.0% w/w, respectively and compressed into tablets weighing 1989 mg on a rotary tablet press. These tablets containing 1500 mg active as Microcaps KCl release slowly over a period of 10 hrs when dissoluted in 0.1 N HCL using USP Apparatus 2.
IlJxample 3 Microcaps KCl granules (KCl crystals microencapsulated in ethylcellulose) with a 87.5 KCl content were coated with an aqueous solution of HPMC and PEG
400 at a ratio of 77/23 to achieve a weight gain of 1.0% w/w. The film coated granules were blended with microcrystalline cellulose, crosslinked PVP and magnesium stearate at 9.5%, 2.0 and 0.5% w/w, respectively and compressed into tablets weighing 1968 mg on a rotary tablet press. These pharmaceutically elegant tablets containing 1500 mg active as Microcaps KCl release slowly over a period of 10 hrs when dissoluted in O.1N HC1 using USP
Apparatus 2.
Ingredients Example 4 Example 5 Example 6 Film Coating Microcaps KCl 1714.3 1714.3 1714.3 PVP (K-30) 31.5 31.5 1 / 1 Ethocel/PVP 31.5 1/1 PEG 400/PEG 4000 3.5 Tri-ethyl citrate 3.5 Dibutyl sebacate 3.5 Compression Mix Film coated KCl 1749.3 1749.3 1749.3 Microcryst. Cellulose194.4 196.6 194.3 Crosslinked PVP 19.6 Total Tablet weight1943.7 1965.5 1943.7 _7_ Example 4 Microcaps KCl granules (KC1 crystals microencapsulated in ethylcellulose) with a 87.5 KCI
content were coated with an aqueous solution of polyvinylpyrrolidone (PVP K-30) containing 1:1 PEG 400/PEG 4000 at 10% w/w to achieve a weight gain of 2.0%
w/w. The film coated granules were blended with microcrystalline cellulose at 10.0% w/w and compressed into tablets weighing 1944 mg on a rotary tablet press. These tablets containing 1500 mg active as Microcaps KCl release slowly over a period of 10 hrs when dissoluted in O.1N HCl using USP Apparatus 2.
Example Microcaps KCl granules (KCl crystals microencapsulated in ethylcellulose) with a 87.5 KCl content were coated to achieve a weight gain of 2.0% w/w with an aqueous solution of PVP
and tri-ethyl citrate at a ratio of 97/03. The film coated granules were blended with microcrystalline cellulose and crosslinked PVP at 10.0 and 1.0% w/w, respectively and compressed into tablets weighing 1965 mg on a rotary tablet press. These tablets containing 1500 mg active as Microcaps KCl release slowly over a period of 10 hrs when dissoluted in O.1N HCl using USP Apparatus 2.
Example 6 Microcaps KCl granules (KCl crystals microencapsulated in ethylcellulose) with a 87.5 KC1 content were coated with an IPA/acetone solution of PVP/Ethocel/DBS at a ratio of 48/48/04 to achieve a weight gain of about 2.0% w/w. The film coated granules were blended with microcrystalline cellulose at 10% w/w and compressed into tablets weighing 1944 mg on a rotary tablet press. These pharmaceutically elegant tablets containing 1500 mg active as Microcaps KC1 release slowly over a period of 10 hrs when dissoluted in O.1N
HCl using USP Apparatus 2.
_g_ The above examples are provided to show how to practice the present invention and are not intended to be exhaustive or to include all obvious modifications and variations which will become apparent to those skilled in formulation development.
However, all these modifications are within the scope of the present invention and by the following claims:
What is claimed is:
Claims (18)
1. A process for preparing a controlled release potassium chloride tablet comprising coating potassium chloride crystals with a first coating of a water insoluble polymeric membrane and a second coating of a plasticized hydrophilic polymer, blending the coated potassium chloride crystals with one or more excipients, and compressing the blend into a tablet.
2. The process of claim 1 wherein the water insoluble polymeric membrane contains ethyl cellulose.
3. The process of claim 2 wherein the step of coating the ethylcellulose membrane includes coacervating said ethylcellulose from a solvent in the presence of polyethylene as the phase induces.
4. The process of claim 2 wherein the primary ethylcellulose membrane has a viscosity of about 90 to 110 cps and is applied to the crystal in an amount of about 8 and about 19%
by weight based on the weight of the potassium chloride crystal.
by weight based on the weight of the potassium chloride crystal.
5. The process of claim 4 wherein the hydrophilic polymer membrane is comprised of a water swellable/water soluble polymer selected from the group consisting of acacia, alginic acid or its salt, corn starch, gelatin, xanthan gum, polyvinylpyrrolidone, sodium carboxymethylcellulose, methylcellulose, ethylcellulose having a viscosity from about 4 to 20 cps and hydroxypropylmethyl cellulose or a combination therof.
6. The process of claim 5 wherein the hydrophilic polymer membrane comprises between about 1 and 4% based on the weight of the ethylcellulose coated crystals.
7. The process of claim 6 wherein the hydrophilic polymeric membrane is formed from a polymer selected from the group consisting of polyvinylpyrrolidone, ethylcellulose and hydroxypropyhnethyl cellulose, and mixtures thereof.
8. The process of claim 7 wherein the hydrophilic polymeric membrane is plasticized with a compound selected from the group consisting of polyethylene glycols, propylene glycol, triethyl citrate, triacetin, dibutyl phthalate and dibutyl sebacate.
9. The process of claim 8 wherein the hydrophilic polymeric membrane is provided by coating the ethylcellulose coated potassium chloride with an aqueous solution containing about 93 parts by weight PVP and about 7 parts by weight PEG 400 and PEG 4000 (weight ratio 1:1) for a weight gain of about 2% w/w.
10. The process of claim 8 wherein the hydrophilic polymeric membrane is provided by coating with an aqueous solution containing PVP and dibutyl sebacate at a ratio of 97 parts by weight to 3 parts by weight.
11. The process of claim 8 wherein the hydrophilic polymeric membrane is provided by coating with an aqueous solution containing HPMC and PEG 400 at a ratio of 93 parts by weight to 7 parts by weight.
12. The process of claim 8 wherein the hydrophilic polymeric membrane is provided by coating with a solution of ethylcellulose, PVP and dibutyl sebacate at a ratio of about 40 to 48 parts by weight ethylcellulose, about 40 to 48 parts PVP and about 2 to 6 parts dibutyl sebacate.
13. The process of claim 1 wherein the excipient is microcrystalline cellulose or hydrous or anhydrous lactose and the excipient is present in an amount of about 5-15%
w/w.
w/w.
14. The process of claim 13 wherein the excipient additionally includes a disintegrant and a lubricant/surfactant.
15. A potassium chloride tablet comprising a compressed mixture of an excipient and potassium chloride crystals, said crystals being coated with a first layer of a water insoluble polymer and a second layer of a plasticized hydrophilic membrane.
16. The tablet of claim 15 wherein potassium chloride is present in an amount effective for the treatment for potassium deficiency in humans.
17. The tablet of claim 16 wherein the amount of potassium chloride is from about 8 mEq to about 20 mEq.
18. The tablet of claim 15 wherein the tablet releases not more than 40% of the potassium chloride they contain in one hr and not less than 80% of the potassium chloride over a period of 8 hrs when tested in USP Apparatus 2 (Paddles @ 50 rpm) in purified water.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46508599A | 1999-12-16 | 1999-12-16 | |
| US09/465,085 | 1999-12-16 | ||
| PCT/US2000/033924 WO2001043725A1 (en) | 1999-12-16 | 2000-12-15 | Controlled release kci tablet formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2394588A1 true CA2394588A1 (en) | 2001-06-21 |
Family
ID=23846434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002394588A Abandoned CA2394588A1 (en) | 1999-12-16 | 2000-12-15 | Controlled release kcl tablet formulations |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1244429A1 (en) |
| AU (1) | AU2101301A (en) |
| CA (1) | CA2394588A1 (en) |
| HK (1) | HK1051320A1 (en) |
| WO (1) | WO2001043725A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7632521B2 (en) * | 2003-07-15 | 2009-12-15 | Eurand, Inc. | Controlled release potassium chloride tablets |
| EP2389174A4 (en) * | 2009-01-22 | 2014-05-07 | Abbot Healthcare Private Ltd | Chronotherapeutic pharmaceutical composition |
| WO2012018056A1 (en) * | 2010-08-03 | 2012-02-09 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Compressed composition |
| CN117122701B (en) * | 2023-08-15 | 2024-04-19 | 河北三禾实创生物科技有限公司 | Potassium chloride granule preparation and preparation method thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3586600T2 (en) * | 1984-02-10 | 1993-02-18 | Benzon Pharma As | DOSAGE CONTAINING A VARIETY WITH A DIFFERENTIAL COVERED UNITS. |
| US5422122A (en) * | 1992-08-04 | 1995-06-06 | Eurand America, Incorporated | Controlled release potassium chloride tablet |
| US5397574A (en) * | 1993-10-04 | 1995-03-14 | Andrx Pharmaceuticals, Inc. | Controlled release potassium dosage form |
| US5840329A (en) * | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
-
2000
- 2000-12-15 EP EP00984388A patent/EP1244429A1/en not_active Withdrawn
- 2000-12-15 CA CA002394588A patent/CA2394588A1/en not_active Abandoned
- 2000-12-15 AU AU21013/01A patent/AU2101301A/en not_active Abandoned
- 2000-12-15 WO PCT/US2000/033924 patent/WO2001043725A1/en not_active Application Discontinuation
-
2003
- 2003-03-27 HK HK03102222.3A patent/HK1051320A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2101301A (en) | 2001-06-25 |
| WO2001043725A1 (en) | 2001-06-21 |
| EP1244429A1 (en) | 2002-10-02 |
| HK1051320A1 (en) | 2003-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4968508A (en) | Sustained release matrix | |
| US6476006B2 (en) | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates | |
| EP0660705B1 (en) | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine | |
| US20030133982A1 (en) | Zero-order sustained release dosage forms and method of making same | |
| US20040052844A1 (en) | Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins | |
| US20040202718A1 (en) | Dosage form for treatment of diabetes mellitus | |
| US20090124702A1 (en) | Pharmaceutical Compositions of Metformin | |
| JPH061716A (en) | Medical prescription having long-term releasability of active ingredient | |
| KR20080007252A (en) | Therapeutic combination in case of benign prostate hyperplasia | |
| US20070160671A1 (en) | Biguanide formulations | |
| TW202038917A (en) | Extended release formulation containing tofacitinib or pharmaceutically acceptable salts thereof and preparation method for the same | |
| US5422122A (en) | Controlled release potassium chloride tablet | |
| WO2009069089A9 (en) | Levetiracetam controlled release composition | |
| CZ298851B6 (en) | Controlled-release tablet for oral administration of active substances | |
| US20100285125A1 (en) | Delivery system for poorly soluble drugs | |
| US8343544B2 (en) | Oral sustained-release tablet | |
| US20050013860A1 (en) | Controlled release potassium chloride tablets | |
| CA2394588A1 (en) | Controlled release kcl tablet formulations | |
| JP3282832B2 (en) | Sustained tablets | |
| JP3592723B2 (en) | Non-disintegrating and sustained capsule formulation | |
| US20040228918A1 (en) | Granule modulating hydrogel system | |
| WO2008038106A1 (en) | Venlafaxine extended release formulations | |
| TW201729814A (en) | Solid preparation | |
| AU2002348712A1 (en) | Dosage form for treatment of diabetes mellitus | |
| GB2334212A (en) | Modified release matrix formulation for cefaclor and cephalexin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |